Home  »  Companies   »  What Are The Analysts’ Predictions For Arrow...

What Are The Analysts’ Predictions For Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)?

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) price closed higher on Friday, February 09, jumping 32.56% below its previous close.

A look at the daily price movement shows that the last close reads $55.15. The company’s 5Y monthly beta was ticking 0.77. Taking into account the 52-week price action we note that the stock hit a 52-week high of $42.48 and 52-week low of $20.67. The stock subtracted -17.47% on its value in the past month.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Arrowhead Pharmaceuticals Inc., which has a market valuation of $4.03 billion, is expected to release its quarterly earnings report Apr 30, 2024 – May 06, 2024. Analysts tracking ARWR have forecast the quarterly EPS to shrink by -0.21 per share this quarter, while the same analysts predict the annual EPS to hit -$2.76 for the year 2024 and up to -$2.67 for 2025. In this case, analysts estimate an annual EPS growth of -43.70% for the year and 3.30% for the next year.

Staying with the analyst view, there is a consensus estimate of $133.49 million for the company’s annual revenue in 2024. Per this projection, the revenue is forecast to grow -44.50% below that which the company brought in 2024.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 9 upward and no downward reviews. On the technical perspective front, indicators give ARWR a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.

The overview shows that ARWR’s price is at present -54.81% off the SMA20 and -94.32% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 50.12, with weekly volatility standing at 6.57%. The indicator jumps to 5.17% when calculated based on the past 30 days. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s beta value is holding at 0.72, while the average true range (ATR) indicator is currently reading 1.91.

Turning out attention to how the Arrowhead Pharmaceuticals Inc. stock has performed in comparison to its peers in the industry, here’s what we find: ARWR’s stock is 32.56% on the day and -0.06% in the past 12 months, while Ionis Pharmaceuticals Inc. (IONS) traded 2.84%% in the last session and was positioned 29.57% up on its price 12 months ago. Turning out attention to how the Arrowhead Pharmaceuticals Inc. stock has performed in comparison to its peers in the industry, here’s what we find: ARWR’s stock is 32.56% on the day and -0.06% in the past 12 months, while Ionis Pharmaceuticals Inc. (IONS) traded 2.84%% in the last session and was positioned 29.57% up on its price 12 months ago. Another comparison is with Johnson & Johnson (JNJ) whose stock price was up 0.23%% in the last trading session, and has flourished -3.68% over the past year. Also, Ligand Pharmaceuticals Inc. (LGND) showed up trend of 0.62%% while its price kept floating at 6.44% over the past year.

An analysis of the Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stock in terms of its daily trading volume indicates that the 3-month average is 0.92. However, this figure increases on the past 10-day timeline to an average of 1.25 million.

Current records show that the company has 123.90M in outstanding shares. The insiders’ percentage holdings are 6.01% of outstanding shares while the percentage share held by institutions stands at 61.34%. The stats also highlight that short interest as of Jan 31, 2024, stood at 7.72 million shares, which puts the short ratio at the time at 4.05. From this we can glean that short interest is 6.23% of company’s current outstanding shares. Notably, we see that shares short in January rose slightly given the previous month’s figure stood at 7.47 million. But the 6.41% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.